Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CLARITY LABORATORIES LLC

NPI: 1780125633 · WARREN, NJ 07059 · Clinical Medical Laboratory · NPI assigned 03/11/2017

$31.73M
Total Medicaid Paid
525,148
Total Claims
288,006
Beneficiaries
85
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialLABORATORIES, CLARITY (AUTHORIZED OFFICIAL)
NPI Enumeration Date03/11/2017

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 24,626 $2.91M
2019 73,976 $7.74M
2020 93,117 $8.59M
2021 125,668 $5.74M
2022 115,906 $3.27M
2023 62,131 $2.01M
2024 29,724 $1.46M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 222,191 82,451 $10.72M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 42,819 17,002 $8.57M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 23,297 9,185 $3.73M
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 50,017 36,153 $3.27M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 17,178 7,736 $2.08M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 24,843 14,885 $2.06M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 32,786 26,617 $663K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 28,569 21,792 $336K
80061 Lipid panel 6,726 5,992 $33K
G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source 2,276 950 $32K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3,751 3,186 $30K
80053 Comprehensive metabolic panel 8,041 7,239 $22K
84443 Thyroid stimulating hormone (TSH) 5,047 4,500 $21K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 580 430 $18K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 10,233 8,951 $15K
82607 2,495 2,217 $15K
83036 Hemoglobin; glycosylated (A1C) 5,926 5,259 $11K
84439 3,100 2,721 $9K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 72 72 $9K
84481 1,561 1,464 $8K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 168 156 $7K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 682 496 $6K
82746 1,363 1,236 $5K
87581 678 492 $5K
87486 679 493 $5K
86769 216 214 $4K
80164 743 677 $3K
86803 276 257 $3K
83735 3,171 2,761 $3K
84153 554 495 $3K
82728 769 715 $3K
36415 Collection of venous blood by venipuncture 6,945 5,826 $3K
80050 General health panel 72 62 $2K
84154 371 333 $2K
82550 885 778 $1K
84550 1,417 1,264 $1K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 108 97 $1K
86480 55 50 $1K
86704 128 120 $1K
87340 178 166 $1K
82248 515 481 $1K
86706 157 148 $984.90
84466 298 280 $932.58
84146 100 92 $891.64
83540 939 856 $852.25
87350 83 79 $790.93
81003 2,154 1,941 $785.00
80178 138 124 $734.40
86708 107 100 $720.54
84436 1,128 1,040 $675.59
82043 1,175 926 $659.79
86707 76 72 $628.62
86141 125 120 $621.32
84479 1,123 1,035 $603.61
83550 584 520 $419.24
84480 1,054 974 $398.93
82150 208 195 $387.00
86592 590 531 $220.49
85652 595 538 $209.50
82570 852 619 $198.83
82274 176 148 $196.10
80048 Basic metabolic panel (calcium, ionized) 81 68 $173.82
86431 121 100 $132.35
82947 88 69 $128.86
86705 122 114 $125.15
85045 176 166 $125.00
84132 64 58 $101.60
84100 151 150 $64.00
85610 58 50 $57.00
86709 75 72 $45.70
84295 63 57 $33.22
85730 32 32 $33.00
84075 87 68 $32.40
84315 38 26 $21.00
84311 39 27 $7.50
82374 63 57 $3.30
82435 63 57 $3.00
84520 87 68 $3.00
82247 126 92 $3.00
84460 86 68 $3.00
84450 86 68 $3.00
82310 87 68 $3.00
82040 87 68 $1.80
84155 87 68 $1.80
83986 38 26 $0.00